(INDIANAPOLIS, July 12, 2022) Dr. Rojeet Shrestha, Technical Director for Patients Choice Laboratories, has been recognized as one of the 40 Under Forty by the American Society for Clinical Pathology's (ASCP).
ASCP’s 40 Under Forty program shines the spotlight on 40 highly-accomplished pathologists, pathology residents and laboratory professionals under age 40 who have made significant contributions to the profession and stand out as leaders who will help shape the future of pathology and laboratory medicine on behalf of patients. The 40 Under Forty designation has made a powerful impact on its honorees, ranging from recognition by others in their home institutions and in the laboratory professions to media attention.
At Patients Choice Laboratories, Dr. Shrestha brings a wealth of knowledge and experience to provide technical oversight and ensure quality results for better health care.
"Patients Choice Laboratories is fortunate to have Dr. Shrestha on our team," said Brad Moss, President of Patients Choice Laboratories. "He is one of the best and most passionate laboratorians I have ever met. His knowledge base in multiple modalities and technologies is wide and deep. He is a true leader and innovator in the field and PCL is in great hands with Dr. Shrestha as the Technical Director."
Dr. Shrestha completed his doctoral and post-doctoral training at Hokkaido University in Japan and specialized in lipoproteins and vascular diseases. He received a bachelor's degree in medical laboratory sciences at Rajiv Gandhi University of Health Sciences, India, and a master's degree in clinical biochemistry at the Institute of Medicine, Tribhuvan University, in Nepal.
He was also involved in teaching-learning activities with medical students as a lecturer of clinical biochemistry at Nepal Medical College & Teaching Hospital, Nepal from 2010 to 2012, and as an assistant professor at the Division of Medical Laboratory Science, Hokkaido University, Japan from 2013 to 2020.
Having extensive experience in developing lipid testing and biomarkers for risk stratification of cardiovascular diseases he has authored more than 50 scientific publications, and has been recognized with numerous awards, one of which, being named to The Pathologist’s 2018 Power List of 100 most influential pathologists. He believes that effective test utilization is crucial for a sustainable healthcare economy and has been a part of the team who founded and built the first automated test utilization management platform called, Laboratory Decision System (LDS).
Later this summer, public voting along with committee selection will identify the top five individuals from the 40 honorees. All 40 honorees will receive:
Complimentary access to one of ASCP’s Certificate Programs (Lab Management University, University of Pathology Informatics, or Leadership Institute),
A professionally-crafted press release for employers and personal networks, and Recognition in ASCP’s renowned Critical Values.
Five individuals are selected as the 40 Under Forty Top Five through a combination of public voting and committee selection. The Top 5 honorees receive complimentary registration and a travel stipend to attend ASCP’s Annual Meeting in Chicago, where they will be recognized as part of the organization’s 100th anniversary events. Use the link below to help elevate Dr. Shrestha to the Top Five by voting for him daily.
Founded in 1922 in Chicago, ASCP is the world’s largest professional membership organization for pathologists and laboratory professionals. ASCP provides excellence in education, certification, and advocacy on behalf of patients, anatomic and clinical pathologists, and medical laboratory professionals. To learn more, visit http://www.ascp.org. Follow us on Twitter at http://www.twitter.com/ascp_chicago and connect with us on Facebook at http://www.facebook.com/ASCP.Chicago.
Patients Choice Laboratories (PCL), based in Indianapolis, Indiana, is a leading provider of comprehensive laboratory testing throughout the United States. Since 2013 PCL has served patients and providers with a focus on providing fast, accurate, and reliable results. Specializing in industry-leading molecular and toxicology diagnostics, PCL provides precise and specific results allowing for quick diagnoses and treatment of patients. With unmatched and innovative molecular testing services for COVID-19, respiratory, urinary tract, wound, women’s health, and nail infections, PCL can provide treatment recommendations based on antibiotic-resistant genes to improve antimicrobial stewardship and patient outcomes.
PCL is at the forefront of infectious diseases, pharmacogenetics, and toxicology diagnostics to ensure the health of our communities now and into the future. Learn more about how we are pioneering new ways to provide patient care on our website: www.pclabsdx.com.